Evotec (EVT) Q4 2025 earnings summary

Executive summary

• Achieved high-end 2025 financials with disciplined cost and CAPEX control, laying groundwork for sustainable, profitable growth through a new strategy focused on scientific leadership, operational excellence, and monetization of biologics.

• Launched the Horizon transformation initiative to optimize operations, science, and commercial execution, targeting €75 million in structural run-rate savings by end-2027, with first benefits expected in H2 2026.

• Key partnerships advanced, including BMS (oncology, neuroscience), Bayer (kidney disease), and a landmark $650 million Sandoz transaction, resulting in milestone payments and clinical progress.

• Strengthened commercial execution with new leadership, including the appointment of a new Chief Commercial Officer and Supervisory Board Chairman nominee, and early positive trends in commercial funnel activity.

• Just - Evotec Biologics pivoted to a technology-focused model, highlighted by the Sandoz agreement and expanded global health collaborations.

Financial highlights

• FY 2025 group revenues reached €788.4 million (up to €810.4 million CER), with Q4 revenues of €253.3 million, and adjusted group EBITDA of €41.1 million (up to €52.3 million CER); both at the high end of guidance.

• D&PD segment revenues declined 13.5% to €528.9 million, while Just-Evotec Biologics revenues surged 39.8% to €259.4 million.

• Adjusted group EBITDA increased 81.9% year-over-year; Q4 adjusted EBITDA more than doubled to €58.0 million.

• R&D expenses decreased to €37.5 million, below guidance, reflecting cost discipline.

• Cash liquidity at year-end 2025 was €476 million, with a net cash position and no active financial covenants.

• CapEx spend reduced 38% year-over-year, supporting a capital-efficient model.

Outlook and guidance

• 2026 is a transition year; group revenues guided at €700–780 million (incurred FX) and €730–810 million (constant FX), with adjusted group EBITDA expected at €0–40 million (incurred FX) and €10–50 million (constant FX).

• H1 2026 expected to remain soft; H2 to benefit from market recovery, new partnerships, and Horizon savings.

• By 2030, group revenues expected to exceed €1 billion, with adjusted EBITDA margin reaching 20% by 2028 and exceeding it by 2030.